Bismarck stem cell clinic investigated after complaints – Seattle Times
|
Bismarck stem cell clinic investigated after complaints
Seattle Times BISMARCK, N.D. (AP) — The North Dakota Attorney General’s office is investigating a Bismarck stem cell clinic. The Bismarck Tribune reports that the attorney general’s Consumer Protection Division initiated a formal investigation of West 2 North … |
|
Eternity Healthcare Inc. Announces Plans to Build a 50000 Square Foot Stem Cell Facility in Tongren, Guizhou, China
Business Wire (press release) Eternity is in preliminary negotiations regarding the specific terms of the license, whereby the Company will acquire the exclusive right to use Shenzhen Zoken Biotechnology’s technology for the harvesting, storage, transformation and application of … |
Washington Post |
In a first, scientists edit genes inside a man’s body to try to cure a disease. What’s next?
Washington Post Scientists have attempted to cure a patient with a rare genetic disorder by rewriting the DNA inside his body, in a first-of-its-kind therapy they hope could one day be applied to numerous other conditions including hemophilia and sickle cell disease. A human has been injected with gene editing tools to cure his disabling disease. Here’s what you need to knowScience Magazine Gene editing, in a patient’s body, attempted for 1st time – CNNCNN US man with rare disease is first to undergo gene editing in the bodyCBS News BBC News –The Verge –The Atlantic –Genetics Home Reference all 78 news articles » |
Seeking Alpha |
Integrated BioSci Research On Atara Biotherapeutics: What’s Next After CAR–T?
Seeking Alpha The approval of Yescarta proved that CAR-T (based on CD4 T cells) works. Atara uses a similar mechanism of action and targets the CAR-T (that leverages on CD8). Data for ATA-129 for EBV franchise is robust. Phase 1 results for the MS franchise is also … |
Endpoints News |
You want to charge $1M for that gene therapy? Here’s where you’re wrong
Endpoints News Spark Therapeutics $ONCE doesn’t have a green light yet from the FDA to sell its gene therapy for one small group of patients with a genetic flaw that causes inherited blindness. And company execs haven’t told anyone exactly what its wholesale price … |